期刊
SEMINARS IN THROMBOSIS AND HEMOSTASIS
卷 38, 期 1, 页码 31-37出版社
THIEME MEDICAL PUBL INC
DOI: 10.1055/s-0031-1300949
关键词
heparin-induced thrombocytopenia; treatment; therapy; anticoagulants
资金
- [K12HL087064]
Heparin-induced thrombocytopenia (HIT) is a prothrombotic complication of heparin therapy. Little more than a decade ago, no effective agents were available to treat this devastating and potentially fatal disease. Since that time, driven by an increased understanding of pathogenesis, the management of HIT has undergone a revolution. Several effective agents for the treatment and prevention of HIT-associated thrombosis are now available. These drugs have transformed the natural history of the disease, dramatically reducing the incidence of thrombosis. Nevertheless, available therapies remain far from ideal. Anticoagulants currently approved for the treatment of HIT are expensive, complex to manage, and carry a substantial bleeding risk. Fortunately, a pipeline of agents await that hold the promise of greater safety, convenience, and cost-effectiveness. The objectives of this review are to discuss currently available drugs for the treatment of HIT, highlight the limitations of these agents, and examine future therapies.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据